Cargando…

PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma

BACKGROUND AND AIM: The proline rich mitotic checkpoint control factor (PRCC) is involved in the splicing process of pre-mRNA. This study aims to elucidate PRCC molecular function, regulatory mechanism and diagnostic value in hepatocellular carcinoma (HCC). METHODS: The tissue microarray and serum s...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chunying, Lin, Xuejing, Sun, Bin, Mao, Ziming, Chen, Lei, Qian, Haihua, Su, Changqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555229/
https://www.ncbi.nlm.nih.gov/pubmed/34715922
http://dx.doi.org/10.1186/s13578-021-00699-x
_version_ 1784591936261193728
author Liu, Chunying
Lin, Xuejing
Sun, Bin
Mao, Ziming
Chen, Lei
Qian, Haihua
Su, Changqing
author_facet Liu, Chunying
Lin, Xuejing
Sun, Bin
Mao, Ziming
Chen, Lei
Qian, Haihua
Su, Changqing
author_sort Liu, Chunying
collection PubMed
description BACKGROUND AND AIM: The proline rich mitotic checkpoint control factor (PRCC) is involved in the splicing process of pre-mRNA. This study aims to elucidate PRCC molecular function, regulatory mechanism and diagnostic value in hepatocellular carcinoma (HCC). METHODS: The tissue microarray and serum samples from HCC patients were used to investigate the clinical value of PRCC. The biological function and molecular mechanism of PRCC were demonstrated by cell biology, biochemical and animal experiments. The relationship between PRCC and intratumoral heterogeneity (ITH) was analyzed by bioinformatics. RESULTS: PRCC was highly expressed in HCC tissues and related to the poor prognosis of HCC patients, its contents were elevated in the preoperative sera of HCC patients. PRCC exhibited high application potential as a substitute or adjuvant of alpha-fetoprotein (AFP) for clinical diagnosis of HCC. It had no significant effect on the proliferation of cancer cells, but could inhibit spheroid formation and metastasis of HCC cells in vitro and in vivo. The high ectopic expression of PRCC made cancer cells insensitive to DNA damage, and enhanced the heterogeneity of HCC cells by inhibiting the JNK/ATM/ATR/ATF2 axis. The HCC patients with high PRCC expression had high ITH, which corresponded to a short overall survival in patients. CONCLUSIONS: PRCC has high application potential as a substitute or adjuvant of AFP for clinical diagnosis of HCC. The high ectopic expression of PRCC not only caused HCC cells to resist to cell death induced by DNA damage, but also endowed cancer cells with numerous DNA mutations to become increasingly heterogeneous, finally leading to a poor prognosis in HCC patients. These data suggested PRCC could be a promising therapeutic target in HCC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-021-00699-x.
format Online
Article
Text
id pubmed-8555229
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85552292021-10-29 PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma Liu, Chunying Lin, Xuejing Sun, Bin Mao, Ziming Chen, Lei Qian, Haihua Su, Changqing Cell Biosci Research BACKGROUND AND AIM: The proline rich mitotic checkpoint control factor (PRCC) is involved in the splicing process of pre-mRNA. This study aims to elucidate PRCC molecular function, regulatory mechanism and diagnostic value in hepatocellular carcinoma (HCC). METHODS: The tissue microarray and serum samples from HCC patients were used to investigate the clinical value of PRCC. The biological function and molecular mechanism of PRCC were demonstrated by cell biology, biochemical and animal experiments. The relationship between PRCC and intratumoral heterogeneity (ITH) was analyzed by bioinformatics. RESULTS: PRCC was highly expressed in HCC tissues and related to the poor prognosis of HCC patients, its contents were elevated in the preoperative sera of HCC patients. PRCC exhibited high application potential as a substitute or adjuvant of alpha-fetoprotein (AFP) for clinical diagnosis of HCC. It had no significant effect on the proliferation of cancer cells, but could inhibit spheroid formation and metastasis of HCC cells in vitro and in vivo. The high ectopic expression of PRCC made cancer cells insensitive to DNA damage, and enhanced the heterogeneity of HCC cells by inhibiting the JNK/ATM/ATR/ATF2 axis. The HCC patients with high PRCC expression had high ITH, which corresponded to a short overall survival in patients. CONCLUSIONS: PRCC has high application potential as a substitute or adjuvant of AFP for clinical diagnosis of HCC. The high ectopic expression of PRCC not only caused HCC cells to resist to cell death induced by DNA damage, but also endowed cancer cells with numerous DNA mutations to become increasingly heterogeneous, finally leading to a poor prognosis in HCC patients. These data suggested PRCC could be a promising therapeutic target in HCC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-021-00699-x. BioMed Central 2021-10-29 /pmc/articles/PMC8555229/ /pubmed/34715922 http://dx.doi.org/10.1186/s13578-021-00699-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Chunying
Lin, Xuejing
Sun, Bin
Mao, Ziming
Chen, Lei
Qian, Haihua
Su, Changqing
PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma
title PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma
title_full PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma
title_fullStr PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma
title_full_unstemmed PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma
title_short PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma
title_sort prcc reduces the sensitivity of cancer cells to dna damage by inhibiting jnk and atm/atr pathways and results in a poor prognosis in hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555229/
https://www.ncbi.nlm.nih.gov/pubmed/34715922
http://dx.doi.org/10.1186/s13578-021-00699-x
work_keys_str_mv AT liuchunying prccreducesthesensitivityofcancercellstodnadamagebyinhibitingjnkandatmatrpathwaysandresultsinapoorprognosisinhepatocellularcarcinoma
AT linxuejing prccreducesthesensitivityofcancercellstodnadamagebyinhibitingjnkandatmatrpathwaysandresultsinapoorprognosisinhepatocellularcarcinoma
AT sunbin prccreducesthesensitivityofcancercellstodnadamagebyinhibitingjnkandatmatrpathwaysandresultsinapoorprognosisinhepatocellularcarcinoma
AT maoziming prccreducesthesensitivityofcancercellstodnadamagebyinhibitingjnkandatmatrpathwaysandresultsinapoorprognosisinhepatocellularcarcinoma
AT chenlei prccreducesthesensitivityofcancercellstodnadamagebyinhibitingjnkandatmatrpathwaysandresultsinapoorprognosisinhepatocellularcarcinoma
AT qianhaihua prccreducesthesensitivityofcancercellstodnadamagebyinhibitingjnkandatmatrpathwaysandresultsinapoorprognosisinhepatocellularcarcinoma
AT suchangqing prccreducesthesensitivityofcancercellstodnadamagebyinhibitingjnkandatmatrpathwaysandresultsinapoorprognosisinhepatocellularcarcinoma